TG Therapeutics Inc. (TGTX) Sets New 12-Month Low at $5.61
TG Therapeutics Inc. (NASDAQ:TGTX) shares reached a new 52-week low on Monday . The stock traded as low as $5.61 and last traded at $5.84, with a volume of 169,566 shares traded. The stock had previously closed at $5.86.
TGTX has been the subject of several research analyst reports. Roth Capital reissued a “buy” rating and issued a $33.00 price objective on shares of TG Therapeutics in a research report on Thursday, June 9th. FBR & Co reaffirmed a “buy” rating on shares of TG Therapeutics in a research report on Monday, June 13th. Zacks Investment Research lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 10th. Brean Capital reaffirmed a “buy” rating on shares of TG Therapeutics in a research report on Monday, June 13th. Finally, SunTrust Banks Inc. assumed coverage on TG Therapeutics in a research report on Friday, May 27th. They issued a “buy” rating and a $18.00 target price for the company. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. TG Therapeutics presently has an average rating of “Buy” and an average target price of $22.33.
The stock’s 50-day moving average price is $6.71 and its 200-day moving average price is $8.22. The company’s market capitalization is $304.45 million.
TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.08. Analysts expect that TG Therapeutics Inc. will post ($1.15) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in TG Therapeutics stock. New York State Common Retirement Fund boosted its position in TG Therapeutics Inc. (NASDAQ:TGTX) by 23.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 223,851 shares of the biopharmaceutical company’s stock after buying an additional 42,933 shares during the period. New York State Common Retirement Fund owned approximately 0.43% of TG Therapeutics worth $2,671,000 as of its most recent SEC filing.
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.